{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-262152","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2022-10-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.835020+00:00","generated_at":"2026-06-23T03:55:35.125106+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"IO Biotech appoints Amy Sullivan as CFO effective Oct 15, 2022","bullets":["Amy Sullivan, 53, appointed CFO and Principal Financial Officer, effective October 15, 2022.","Annual base salary of $425,000 and target bonus of 45% of base salary.","Granted option for 288,152 shares; vests 25% at 1 year, then monthly over 3 years.","Ms. Sullivan previously served as CFO at TABA and chief strategy officer at Kiadis Pharma, leading its sale to Sanofi.","She brings 25+ years of life sciences finance and corporate strategy experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-262152","json":"https://secwatch.observer/filing/0001193125-22-262152.json","markdown":"https://secwatch.observer/filing/0001193125-22-262152.md","text":"https://secwatch.observer/filing/0001193125-22-262152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312522262152/0001193125-22-262152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312522262152/d412480d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T03:55:35.125106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f75ad8f16","claim":"Amy Sullivan was appointed as Chief Financial Officer at IO Biotech, Inc..","evidence_excerpt":"On October 13, 2022, IO Biotech, Inc. (the “Company”) appointed Amy Sullivan, 53, as the Company’s Chief Financial Officer, effective as of October 15, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1865494/000119312522262152/0001193125-22-262152-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}